Targeting protein-protein interaction by small molecules.
暂无分享,去创建一个
Weiru Wang | G. Fang | Weiru Wang | Lingyan Jin | Guowei Fang | Lingyan Jin
[1] U. Rapp,et al. Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.
[2] Zhaoyang Wen,et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). , 2012, Journal of medicinal chemistry.
[3] J. Huret,et al. An Atlas on Chromosomes in Hematological Malignancies. Example: 11q23 and MLL partners , 2001, Leukemia.
[4] S. Korsmeyer,et al. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.
[5] Roger L. Williams,et al. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS , 2007, The EMBO journal.
[6] M. Willingham,et al. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. , 1991, The Journal of biological chemistry.
[7] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[8] C. V. van Veelen,et al. Isozymes of pyruvate kinase from human brain, meningiomas, and malignant gliomas. , 1978, Cancer research.
[9] S. Robson,et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.
[10] Marc Therrien,et al. A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.
[11] Jolanta Grembecka,et al. Molecular Basis of the Mixed Lineage Leukemia-Menin Interaction , 2010, The Journal of Biological Chemistry.
[12] M. Lei,et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription , 2012, Nature.
[13] M. Heuser,et al. Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. , 2008, Experimental hematology.
[14] B. Stoddard,et al. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. , 1998, Structure.
[15] L. Johnson,et al. The structural basis for control of eukaryotic protein kinases. , 2012, Annual review of biochemistry.
[16] Mark S. Boguski,et al. Proteins regulating Ras and its relatives , 1993, Nature.
[17] I. Vetter,et al. The Guanine Nucleotide-Binding Switch in Three Dimensions , 2001, Science.
[18] Louis Renault,et al. Arf, Arl, Arp and Sar proteins: a family of GTP‐binding proteins with a structural device for ‘front–back’ communication , 2002, EMBO reports.
[19] Arndt Borkhardt,et al. Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization , 2004, Molecular and Cellular Biology.
[20] P. Bamborough,et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.
[21] J. Whelan. Stapled peptide induces cancer cell death. , 2004, Drug discovery today.
[22] M. Jacobson,et al. Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.
[23] Patrick A. Curmi,et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain , 2004, Nature.
[24] C. Croce,et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality , 2001, Oncogene.
[25] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[26] Tina N. Davis,et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. , 2010, Cancer cell.
[27] G. Sauvageau,et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. , 1997, Blood.
[28] Dean W. Felsher,et al. Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas , 2008, PloS one.
[29] Chi V. Dang,et al. Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.
[30] Stuart L. Schreiber,et al. Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP , 1996, Science.
[31] David R. Liu,et al. DNA-Templated Organic Synthesis and Selection of a Library of Macrocycles , 2004, Science.
[32] W. Macon,et al. T-cell-rich large-B-cell lymphomas contain non-activated CD8+ cytolytic T cells, show increased tumor cell apoptosis, and have lower Bcl-2 expression than diffuse large-B-cell lymphomas. , 1998, The American journal of pathology.
[33] Christian M. Metallo,et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis , 2012, Nature chemical biology.
[34] M. Cleary,et al. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. , 2003, Genes & development.
[35] T. Graeber,et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.
[36] J. Drews,et al. Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.
[37] B. Brandhuber,et al. Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition , 2010, PloS one.
[38] T. Mak,et al. Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.
[39] J. Hess. MLL: a histone methyltransferase disrupted in leukemia. , 2004, Trends in molecular medicine.
[40] I. Mellman,et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.
[41] R. Marais,et al. Melanoma biology and new targeted therapy , 2007, Nature.
[42] E. Sztul,et al. Dissecting the role of the ARF guanine nucleotide exchange factor GBF1 in Golgi biogenesis and protein trafficking , 2007, Journal of Cell Science.
[43] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[44] P. D. Dal Cin,et al. BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). , 2001, The American journal of pathology.
[45] W. Kolch,et al. Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.
[46] William B. Smith,et al. Selective inhibition of BET bromodomains , 2010, Nature.
[47] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[48] Sydney L. Stoops,et al. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape , 2011, Expert opinion on therapeutic patents.
[49] David R. Liu,et al. Highly Specific, Bi-substrate-Competitive Src Inhibitors from DNA-Templated Macrocycles , 2011, Nature chemical biology.
[50] Scott A. Armstrong,et al. MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.
[51] C. Ly,et al. Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres. , 2010, Bioorganic & medicinal chemistry letters.
[52] Richard Marais,et al. The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.
[53] Noel Southall,et al. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Bioorganic & medicinal chemistry letters.
[54] Matthew Meyerson,et al. The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.
[55] J. Fletcher,et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.
[56] Zhijian Zhao,et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[57] J. Acker,et al. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain. , 1999, Molecular cell.
[58] Y Wang,et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.
[59] M. Wigler,et al. Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2. , 1993, Science.
[60] Gerald C. Chu,et al. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.
[61] Raymond E. Moellering,et al. Direct inhibition of the NOTCH transcription factor complex , 2009, Nature.
[62] A. Gingras,et al. Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.
[63] Gideon Bollag,et al. Biochemical and Functional Characterization of Germ Line KRAS Mutations , 2007, Molecular and Cellular Biology.
[64] J. Cherfils,et al. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor , 2003, Nature.
[65] A. Kral,et al. Rapid assembly of diverse and potent allosteric Akt inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[66] L. Vassilev. Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics , 2004, Cell cycle.
[67] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[68] Kenneth Chu,et al. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.
[69] Somasekar Seshagiri,et al. Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers , 2012, Proceedings of the National Academy of Sciences.
[70] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[71] P. Hajduk,et al. Predicting protein druggability. , 2005, Drug discovery today.
[72] D. Barford,et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.
[73] S. Schreiber,et al. Macrolactones in diversity-oriented synthesis: preparation of a pilot library and exploration of factors controlling macrocyclization. , 2004, Journal of combinatorial chemistry.
[74] C. Tse,et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.
[75] Qi Sun,et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. , 2012, Angewandte Chemie.
[76] M. Steinmetz,et al. Structural basis for the regulation of tubulin by vinblastine , 2005, Nature.
[77] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[78] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[79] J. Lippincott-Schwartz,et al. Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin a suggests an ER recycling pathway , 1990, Cell.
[80] G. Verdine,et al. Stapled peptides for intracellular drug targets. , 2012, Methods in enzymology.
[81] Gideon Bollag,et al. GTPase activating proteins: critical regulators of intracellular signaling. , 2002, Biochimica et biophysica acta.
[82] I. Bernstein,et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. , 1994, The Journal of clinical investigation.
[83] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[84] Evripidis Gavathiotis,et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. , 2012, The Journal of clinical investigation.
[85] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[86] H. Christofk,et al. Identification of small molecule inhibitors of pyruvate kinase M2. , 2010, Biochemical pharmacology.
[87] Maksymilian Chruszcz,et al. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. , 2012, Blood.
[88] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[89] W. Herr,et al. Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.
[90] R. Klausner,et al. ADP-ribosylation factor, a small GTP-binding protein, is required for binding of the coatomer protein beta-COP to Golgi membranes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[91] Christopher P Austin,et al. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. , 2010, Journal of medicinal chemistry.
[92] Jolanta Grembecka,et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.
[93] Stephen P. Hale,et al. The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.
[94] Michelle R Arkin,et al. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. , 2003, Journal of the American Chemical Society.
[95] C. Lindsley,et al. Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. , 2008, Bioorganic & medicinal chemistry letters.
[96] Huan Yang,et al. The Akt/PKB pathway: molecular target for cancer drug discovery , 2005, Oncogene.
[97] Kathleen Haskell,et al. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. , 2008, Bioorganic & medicinal chemistry letters.
[98] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[99] B. R. Bowman,et al. Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin , 2012, Proceedings of the National Academy of Sciences.
[100] Derek S. Tan,et al. Expanding the range of 'druggable' targets with natural product-based libraries: an academic perspective. , 2010, Current opinion in chemical biology.
[101] J. Rothman,et al. Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF , 1992, Nature.
[102] Susan S. Taylor,et al. Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers , 2013, Cell.
[103] Maxwell D Cummings,et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.
[104] Daniel R. Caffrey,et al. Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.
[105] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[106] Qiang Zhou,et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.
[107] M. Cleary,et al. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. , 2007, Genes & development.
[108] J. Aster,et al. BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.
[109] Roderick E Hubbard,et al. Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.
[110] Monya Baker,et al. Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.
[111] C. V. van Veelen,et al. L-alpha-alanine inhibition of pyruvate kinase from tumors of the human central nervous system. , 1979, Cancer research.
[112] Jonathan Goldberg,et al. Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism. , 2003, Molecular cell.
[113] O. Warburg,et al. THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.
[114] M. Cleary,et al. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.
[115] Alex M. Clark,et al. 2D Structure Depiction , 2006, J. Chem. Inf. Model..
[116] Qiang Zhou,et al. Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis To Promote G1 Gene Expression and Cell Cycle Progression , 2007, Molecular and Cellular Biology.
[117] J. Drews. Genomic sciences and the medicine of tomorrow , 1996, Nature Biotechnology.
[118] P. Majumder,et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[119] Hieu T. Do,et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.